Brokerages Set Annexon, Inc. (NASDAQ:ANNX) Price Target at $15.80

Shares of Annexon, Inc. (NASDAQ:ANNX - Get Free Report) have earned a consensus rating of "Buy" from the six research firms that are currently covering the company, MarketBeat Ratings reports. Six equities research analysts have rated the stock with a buy recommendation. The average 12 month target price among analysts that have issued a report on the stock in the last year is $15.80.

A number of research firms have recently issued reports on ANNX. Cantor Fitzgerald reissued an "overweight" rating on shares of Annexon in a research report on Wednesday, June 5th. HC Wainwright reaffirmed a "buy" rating and set a $30.00 price objective on shares of Annexon in a research report on Tuesday, August 13th. Wells Fargo & Company dropped their price objective on Annexon from $12.00 to $10.00 and set an "overweight" rating on the stock in a research report on Wednesday, May 15th. Finally, Needham & Company LLC reaffirmed a "buy" rating and set a $16.00 price objective on shares of Annexon in a research report on Tuesday, August 13th.

Institutional Investors Weigh In On Annexon

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ANNX. Ameritas Investment Partners Inc. raised its stake in shares of Annexon by 78.2% in the first quarter. Ameritas Investment Partners Inc. now owns 6,718 shares of the company's stock worth $48,000 after purchasing an additional 2,949 shares during the last quarter. Sandia Investment Management LP purchased a new position in shares of Annexon in the second quarter worth about $49,000. Victory Capital Management Inc. purchased a new position in shares of Annexon in the second quarter worth about $51,000. Tower Research Capital LLC TRC raised its stake in shares of Annexon by 53.2% in the fourth quarter. Tower Research Capital LLC TRC now owns 11,924 shares of the company's stock worth $54,000 after purchasing an additional 4,141 shares during the last quarter. Finally, Principal Financial Group Inc. purchased a new position in shares of Annexon in the second quarter worth about $56,000.

Annexon Stock Performance

Annexon stock traded up $0.09 during mid-day trading on Friday, hitting $5.89. The company's stock had a trading volume of 1,212,073 shares, compared to its average volume of 2,006,131. The company has a 50 day moving average of $5.53 and a 200-day moving average of $5.45. The stock has a market cap of $544.31 million, a PE ratio of -4.01 and a beta of 1.29. Annexon has a one year low of $1.57 and a one year high of $8.40.

Annexon (NASDAQ:ANNX - Get Free Report) last posted its quarterly earnings results on Monday, August 12th. The company reported ($0.23) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.23). On average, equities research analysts forecast that Annexon will post -0.98 EPS for the current fiscal year.

Annexon Company Profile

Annexon, Inc, a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis.